Cutaneous Oncology News

Diagnosis with actinic keratosis at age younger than 49 years or older than 80 years was associated with elevated cutaneous squamous cell carcinoma risk, according to a study.

Among patients with localized Merkel cell carcinoma, surgical margins larger than 1 cm improved survival regardless of factors such as tumor subsite and receipt of adjuvant chemotherapy, according to a study.

A large-scale surveillance program may allow clinicians to detect melanomas earlier in high-risk patients, according to a study.

A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

Patients previously treated with hedgehog inhibitors for locally advanced basal cell carcinoma saw “clinical benefit” when treated with cemiplimab, according to a presentation at South Beach Symposium Medical Dermatology Summit.

A number of epidermal growth factor receptor inhibitors used in the oncology setting continue to demonstrate impacts on keratinocyte growth and cause adverse skin reactions, according to a study.

Mortality associated with Merkle cell carcinoma may be lower among women compared with men, according to a retrospective study.

Klisyri, a topical treatment for actinic keratosis, has been launched by Almirall following a December approval by the FDA, according to a press release.

Pathological response should be an early surrogate endpoint for clinical trials of neoadjuvant therapy for melanoma, according to results of a pooled analysis published in Nature Medicine.

Sonidegib efficacy in patients with locally advanced basal cell carcinoma was not affected by concomitant cardiovascular medications, according to a presentation at Maui Derm for Dermatologists.